-
VectorY Expands PIONEER-ALS Phase 1/2 Clinical Trial Size
29 September 2026 VectorY Expands PIONEER-ALS Phase 1/2 Clinical Trial Size VectorY Therapeutics, a clinical-stage biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases, announced the expansion of its ongoing,… More >>
-
Otsuka Establishes Ulefnersen Early Access Program (EAP) for Eligible People Living with FUS-ALS
22 September 2026 The program reflects Otsuka’s commitment to facilitate early access to investigational medicines outside of a clinical trial, where permitted by local regulations, for people living with rare… More >>
-
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing treatment for FUS-ALS
September 22, 2026 Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing treatment for FUS-ALS Ulefnersen demonstrated a statistically significant improvement on… More >>
-
Community Update: ASTRALS Phase 2 Trial Results in Amyotrophic Lateral Sclerosis
August 25, 2026 Novartis likes to update you on our VHB937B1 program for Amyotrophic Lateral Sclerosis (ALS). As shared previously, recruitment was completed for the ASTRALS Phase 2 clinical trial… More >>
-
First participant in Europe enrolled in PREVAiLS Phase 3 study of pridopidine in ALS
June 17, 2026 Ferrer and Prilenia Therapeutics B.V. announced the enrolment of the first participant in Europe in PREVAiLS (EUCT: 2025-524002-16-00 / NCT07322003), the global Phase 3 study evaluating the efficacy and safety of… More >>
-
VectorY Therapeutics Receives U.K. MHRA Authorization and EMA Approval to Initiate Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People Living with Amyotrophic Lateral Sclerosis (ALS)
April 28, 2026 The authorizations represent an expansion of the PIONEER-ALS clinical trial,currently enrolling participants at clinical trial sites in the U.S. VectorY Therapeutics, a leader in vectorized antibody therapies… More >>
-
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
April 30, 2026 87 percent reduction in risk of death compared to patients who received placebo (hazard ratio: 0.13, p-value: < 0.0001) Corcept Therapeutics, a commercial-stage company engaged in the… More >>
-
Novartis ASTRALS trial with VHB937 in ALS fully enrolled
Community Statement:Enrollment complete for Novartis Phase 2 (ASTRALS) Clinical Trial in amyotrophic lateral sclerosis (ALS) More >>
